geron.com (GERN): חוב להון עצמי

Geron Corporation is expanding sales of myelodysplastic syndromes therapy across hematology centers in the US. This chart on GURU.Markets illustrates the total debt-to-equity ratio, where 1.16 serves as the final level marker. High testing costs and telomerase patents protect the business from competitors, although geopolitical risks and sanctions could hinder the international registration of drugs.

Complex international logistics for active substances require significant capital expenditures from Geron Corporation (GERN) to ensure supply chain stability. This indicator measures the proportion of borrowed funds relative to equity, determining the business's degree of financial leverage. Investors use this metric to assess the company's resilience to rising debt service costs. Low leverage minimizes bankruptcy risks in the event of delays in the commercialization of developments. The trend of the total debt-to-equity ratio on this chart visualizes this balance between debt load and financial independence.